vs

Side-by-side financial comparison of Camden Property Trust (CPT) and IMMUCELL CORP (ICCC). Click either name above to swap in a different company.

IMMUCELL CORP is the larger business by last-quarter revenue ($5.5M vs $5.3M, roughly 1.0× Camden Property Trust). Camden Property Trust runs the higher net margin — 2954.1% vs -2.5%, a 2956.6% gap on every dollar of revenue. On growth, Camden Property Trust posted the faster year-over-year revenue change (243.0% vs -8.4%). Over the past eight quarters, Camden Property Trust's revenue compounded faster (102.8% CAGR vs 3.9%).

Camden Property Trust is a publicly traded real estate investment trust that invests in apartments in the United States. As of December 31, 2023, the company owned interests in 176 apartment communities containing 59,800 apartment homes in the United States. It is the 14th largest owner of apartments in the United States.

ImmuCell Corp is a US-based animal health biotechnology company that develops, manufactures and markets innovative products for livestock, primarily dairy cattle. Its core offerings include preventive and therapeutic solutions for common bovine health issues such as mastitis, serving agricultural producers and veterinary providers across North America.

CPT vs ICCC — Head-to-Head

Bigger by revenue
ICCC
ICCC
1.0× larger
ICCC
$5.5M
$5.3M
CPT
Growing faster (revenue YoY)
CPT
CPT
+251.4% gap
CPT
243.0%
-8.4%
ICCC
Higher net margin
CPT
CPT
2956.6% more per $
CPT
2954.1%
-2.5%
ICCC
Faster 2-yr revenue CAGR
CPT
CPT
Annualised
CPT
102.8%
3.9%
ICCC

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
CPT
CPT
ICCC
ICCC
Revenue
$5.3M
$5.5M
Net Profit
$156.0M
$-139.7K
Gross Margin
42.9%
Operating Margin
0.4%
Net Margin
2954.1%
-2.5%
Revenue YoY
243.0%
-8.4%
Net Profit YoY
283.5%
80.1%
EPS (diluted)
$1.44
$-0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CPT
CPT
ICCC
ICCC
Q4 25
$5.3M
Q3 25
$2.6M
$5.5M
Q2 25
$2.6M
$6.4M
Q1 25
$2.5M
$8.1M
Q4 24
$1.5M
$7.8M
Q3 24
$1.7M
$6.0M
Q2 24
$2.6M
$5.5M
Q1 24
$1.3M
$7.3M
Net Profit
CPT
CPT
ICCC
ICCC
Q4 25
$156.0M
Q3 25
$108.9M
$-139.7K
Q2 25
$80.7M
$501.9K
Q1 25
$38.8M
$1.4M
Q4 24
$40.7M
Q3 24
$-4.2M
$-701.7K
Q2 24
$42.9M
$-1.5M
Q1 24
$83.9M
$-437.9K
Gross Margin
CPT
CPT
ICCC
ICCC
Q4 25
Q3 25
42.9%
Q2 25
43.7%
Q1 25
41.6%
Q4 24
36.5%
Q3 24
26.3%
Q2 24
22.5%
Q1 24
31.6%
Operating Margin
CPT
CPT
ICCC
ICCC
Q4 25
Q3 25
0.4%
Q2 25
8.8%
Q1 25
13.9%
Q4 24
8.0%
Q3 24
-9.6%
Q2 24
-25.3%
Q1 24
-4.1%
Net Margin
CPT
CPT
ICCC
ICCC
Q4 25
2954.1%
Q3 25
4246.9%
-2.5%
Q2 25
3063.8%
7.8%
Q1 25
1561.0%
17.9%
Q4 24
2642.3%
Q3 24
-246.3%
-11.7%
Q2 24
1646.9%
-28.0%
Q1 24
6533.4%
-6.0%
EPS (diluted)
CPT
CPT
ICCC
ICCC
Q4 25
$1.44
Q3 25
$1.00
$-0.02
Q2 25
$0.74
$0.06
Q1 25
$0.36
$0.16
Q4 24
$0.37
$0.09
Q3 24
$-0.04
$-0.09
Q2 24
$0.40
$-0.20
Q1 24
$0.77
$-0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CPT
CPT
ICCC
ICCC
Cash + ST InvestmentsLiquidity on hand
$25.2M
$3.9M
Total DebtLower is stronger
$3.9B
$9.5M
Stockholders' EquityBook value
$4.4B
$29.8M
Total Assets
$9.0B
$45.7M
Debt / EquityLower = less leverage
0.89×
0.32×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CPT
CPT
ICCC
ICCC
Q4 25
$25.2M
Q3 25
$25.9M
$3.9M
Q2 25
$33.1M
Q1 25
$26.2M
Q4 24
$21.0M
$3.8M
Q3 24
$31.2M
Q2 24
$93.9M
$1.3M
Q1 24
$92.7M
$960.3K
Total Debt
CPT
CPT
ICCC
ICCC
Q4 25
$3.9B
Q3 25
$3.7B
$9.5M
Q2 25
$3.8B
Q1 25
$3.7B
$8.7M
Q4 24
$3.5B
$9.0M
Q3 24
$3.5B
$9.4M
Q2 24
$3.6B
$9.8M
Q1 24
$3.6B
$10.2M
Stockholders' Equity
CPT
CPT
ICCC
ICCC
Q4 25
$4.4B
Q3 25
$4.5B
$29.8M
Q2 25
$4.6B
$29.9M
Q1 25
$4.6B
$29.0M
Q4 24
$4.7B
$27.5M
Q3 24
$4.7B
$26.4M
Q2 24
$4.9B
$23.5M
Q1 24
$4.9B
$24.6M
Total Assets
CPT
CPT
ICCC
ICCC
Q4 25
$9.0B
Q3 25
$9.1B
$45.7M
Q2 25
$9.1B
$46.7M
Q1 25
$9.0B
$45.6M
Q4 24
$8.9B
$45.1M
Q3 24
$8.9B
$44.4M
Q2 24
$9.1B
$41.9M
Q1 24
$9.1B
$43.1M
Debt / Equity
CPT
CPT
ICCC
ICCC
Q4 25
0.89×
Q3 25
0.82×
0.32×
Q2 25
0.83×
Q1 25
0.81×
0.30×
Q4 24
0.75×
0.33×
Q3 24
0.73×
0.36×
Q2 24
0.73×
0.42×
Q1 24
0.72×
0.41×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CPT
CPT
ICCC
ICCC
Operating Cash FlowLast quarter
$826.6M
$-1.2M
Free Cash FlowOCF − Capex
$-1.8M
FCF MarginFCF / Revenue
-32.3%
Capex IntensityCapex / Revenue
10.8%
Cash ConversionOCF / Net Profit
5.30×
TTM Free Cash FlowTrailing 4 quarters
$715.4K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CPT
CPT
ICCC
ICCC
Q4 25
$826.6M
Q3 25
$250.9M
$-1.2M
Q2 25
$230.7M
$1.6M
Q1 25
$148.2M
$1.6M
Q4 24
$774.9M
$-3.1K
Q3 24
$261.6M
$-639.3K
Q2 24
$225.1M
$581.8K
Q1 24
$135.9M
$418.5K
Free Cash Flow
CPT
CPT
ICCC
ICCC
Q4 25
Q3 25
$-1.8M
Q2 25
$1.4M
Q1 25
$1.2M
Q4 24
$-199.3K
Q3 24
$-727.7K
Q2 24
$471.0K
Q1 24
$348.1K
FCF Margin
CPT
CPT
ICCC
ICCC
Q4 25
Q3 25
-32.3%
Q2 25
22.4%
Q1 25
15.4%
Q4 24
-2.6%
Q3 24
-12.1%
Q2 24
8.6%
Q1 24
4.8%
Capex Intensity
CPT
CPT
ICCC
ICCC
Q4 25
Q3 25
10.8%
Q2 25
2.4%
Q1 25
4.1%
Q4 24
2.5%
Q3 24
1.5%
Q2 24
2.0%
Q1 24
1.0%
Cash Conversion
CPT
CPT
ICCC
ICCC
Q4 25
5.30×
Q3 25
2.30×
Q2 25
2.86×
3.19×
Q1 25
3.82×
1.09×
Q4 24
19.04×
Q3 24
Q2 24
5.24×
Q1 24
1.62×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons